10.11.2026
New Alzheimer’s trial could help find treatments faster
A first-of-its-kind UK clinical trial that could cut years off the search for effective Alzheimer’s treatments is now recruiting participants through Join Dementia Research.
The national trial, called AD-SMART (Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial), uses an innovative platform design to test several potential medicines at once.
The study will begin by testing treatments designed for type 2 diabetes and attention deficit hyperactivity disorder (ADHD). The aim is to examine whether the drugs can lessen symptoms such as memory and thinking problems.
The treatments will be tested against a placebo, for comparison.
The study team checks results at regular stages throughout the trial.
Any drug that does not show clear benefit can be dropped quickly, while new promising treatments are added to the platform.
This adaptive approach speeds up testing timelines by more than half. This will also reduce costs and ensure more participants receive an active treatment rather than a placebo.
Around 600,000 people in the UK live with Alzheimer's disease. Currently, there are no NHS treatments that slow or stop its underlying progression.
AD-SMART directly addresses this urgent care gap by adapting testing methods previously proven in cancer and motor neuron disease research.
Professor Paresh Malhotra, Chief Investigator and NIHR National Specialty Lead for Dementia and Neurodegeneration, said:
“For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we’ve found something that works.
“We are applying advances from cancer and other conditions to accelerate testing of treatments for people with Alzheimer's disease. The way AD-SMART is set up means we’re testing several treatments at the same time, and those that don’t show promise can be quickly stopped. Then we can start testing something else. That’s the best way to get effective treatments to patients as quickly as we can.”
Prime Minister Andy Burnham said:
"I know how it feels to lose a loved one to dementia and have seen first-hand the devastating impact this illness has on families.
“That's why I’m proud to see this trial being launched in the UK, so that cutting edge treatments can reach patients here as soon as possible.
“I have made dementia research a national priority. I want Britain to be the leading nation, making the breakthroughs that change people’s lives.”
The study is led by the UK Dementia Research Institute and Alzheimer’s Research UK. It is delivered in partnership with the National Institute for Health and Care Research (NIHR) , Medical Research Council, Health Data Research UK.
Recruitment is already open at NHS trusts in the following locations:
London
Cambridgeshire
Surrey
Edinburgh
Southampton
Over the next 18 months, up to 20 NHS sites will open across the UK. Researchers aim to recruit 1,200 participants nationwide over the next 4 years.
The study is also using Join Dementia Research to find eligible volunteers to take part.
People with a confirmed Alzheimer’s diagnosis may be eligible to take part. Log in to your Join Dementia Research account to see if you have been invited to participate. If you do not already have an account, sign up today.